Drug:
Reaction: EXPOSURE VIA SKIN CONTACT
20260101 - 20261231
No. 501 - 600
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 501 | 26419244 |
US |
57 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 502 | 26419265 |
US |
53 | 2 |
Exposure via skin contact, Accidental exposure to product, Underdose, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 503 | 26419437 |
US |
75 | 1 |
Cerebrovascular accident, Vocal cord disorder, Prostate cancer, Hemiplegia, Balance disorder, Macular degeneration, Eye pain, Neoplasm malignant, Cerebral haemorrhage, Pruritus, Product dose omission issue, Exposure via skin contact, Accidental exposure to product, Formication, Confusional state, Weight increased, Fatigue, Memory impairment, Visual impairment, Myopia, Cognitive disorder, Neoplasm, Neurodermatitis, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, NIFEDIPINE, CLONAZEPAM, LISINOPRIL, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, VENLAFAXINE HYDROCHLORIDE, DEXTROAMPHETAMINE, |
||||
| 504 | 26419507 |
US |
28 | 2 |
Dermatitis atopic, Rash, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 505 | 26419515 |
US |
2 | |
Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 506 | 26419566 |
US |
66 | 1 |
Injection site urticaria, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 507 | 26418010 |
US |
58 | 1 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 508 | 26418026 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, ESCITALOPRAM, CETIRIZINE HYDROCHLORIDE, |
||||
| 509 | 26418136 |
US |
69 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 510 | 26418147 |
US |
72 | 1 |
Injection site pain, Injection site mass, Accidental exposure to product, Exposure via skin contact, Wrong technique in product usage process, |
||||
EVOLOCUMAB, EZETIMIBE, ROSUVASTATIN, |
||||
| 511 | 26418194 |
GB |
39 | |
Abortion spontaneous, Condition aggravated, Joint microhaemorrhage, Pain, Haemorrhage, Psoriasis, Intentional dose omission, Accidental exposure to product, Exposure via skin contact, |
||||
ADALIMUMAB-AATY, ADALIMUMAB-AATY, |
||||
| 512 | 26418216 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 513 | 26418262 |
US |
40 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 514 | 26418270 |
US |
47 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 515 | 26418322 |
US |
74 | 2 |
Pruritus, Incorrect dose administered, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, CALCIUM, FISH OIL, MAGNESIUM, PREDNISONE, VITAMIN C, ERGOCALCIFEROL, VITAMIN E, |
||||
| 516 | 26418853 |
US |
79 | 2 |
Exposure via skin contact, Accidental exposure to product, Wrong technique in device usage process, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 517 | 26418892 |
US |
78 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 518 | 26418896 |
US |
29 | 1 |
Injection site pain, Injection site bruising, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 519 | 26413089 |
US |
65 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 520 | 26413170 |
US |
2 | |
Ocular hyperaemia, Product delivery mechanism issue, Accidental exposure to product, Circumstance or information capable of leading to medication error, Exposure via skin contact, |
||||
| 521 | 26413266 |
US |
68 | 1 |
Accidental exposure to product, Device delivery system issue, Device deployment issue, Exposure via skin contact, |
||||
ABATACEPT, EVOLOCUMAB, |
||||
| 522 | 26413925 |
US |
65 | 2 |
Wrong technique in product usage process, Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 523 | 26414245 |
US |
78 | 1 |
Product dose omission issue, Exposure via skin contact, Wrong technique in product usage process, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 524 | 26414449 |
US |
37 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 525 | 26415219 |
US |
75 | 2 |
Exposure via skin contact, Accidental exposure to product, Underdose, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 526 | 26416097 |
US |
1 | |
Wrong technique in device usage process, Accidental exposure to product, Device leakage, Exposure via skin contact, Underdose, |
||||
SECUKINUMAB, |
||||
| 527 | 26416115 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Device leakage, Device delivery system issue, |
||||
SECUKINUMAB, |
||||
| 528 | 26416118 |
US |
61 | 2 |
Device operational issue, Accidental exposure to product, Exposure via skin contact, Product dose omission issue, |
||||
ABATACEPT, |
||||
| 529 | 26416153 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Device delivery system issue, Device deployment issue, |
||||
SECUKINUMAB, |
||||
| 530 | 26416464 |
US |
1 | |
Product dispensing error, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 531 | 26416484 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE-YFGN, INSULIN GLARGINE, |
||||
| 532 | 26416504 |
US |
54 | 2 |
Throat cancer, Injection site rash, Injection site swelling, Accidental exposure to product, Exposure via skin contact, Rash, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 533 | 26416550 |
US |
55 | 2 |
Injection site swelling, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 534 | 26416587 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 535 | 26416602 |
US |
16 | 2 |
Eczema, Incorrect dose administered by device, Device operational issue, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered, |
||||
DUPILUMAB, |
||||
| 536 | 26416641 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 537 | 26416654 |
US |
41 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 538 | 26416691 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 539 | 26416709 |
US |
74 | 1 |
Sneezing, Cough, Nasal congestion, Inappropriate schedule of product administration, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 540 | 26416730 |
US |
17 | 1 |
Exposure via skin contact, Accidental exposure to product, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 541 | 26416827 |
US |
77 | 2 |
Exposure via skin contact, Product communication issue, Accidental exposure to product, |
||||
EVOLOCUMAB, TIRZEPATIDE, |
||||
| 542 | 26416863 |
US |
82 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 543 | 26417310 |
US |
71 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 544 | 26417618 |
US |
47 | 2 |
Exposure via skin contact, Product dose omission issue, No adverse event, Syringe issue, Device malfunction, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 545 | 26406547 |
US |
21 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 546 | 26406559 |
US |
11 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 547 | 26406752 |
US |
68 | 1 |
Exposure via skin contact, Accidental exposure to product, Underdose, Product complaint, |
||||
MEPOLIZUMAB, |
||||
| 548 | 26406855 |
US |
48 | 2 |
Accidental exposure to product, Exposure via skin contact, Drug dose omission by device, Device difficult to use, |
||||
EVOLOCUMAB, |
||||
| 549 | 26406952 |
US |
60 | 2 |
Device difficult to use, Accidental exposure to product, Exposure via skin contact, Incorrect dose administered by device, |
||||
EVOLOCUMAB, |
||||
| 550 | 26408648 |
GB |
76 | 1 |
Parkinson^s disease, Exposure via skin contact, Accidental exposure to product, |
||||
ALIROCUMAB, |
||||
| 551 | 26409142 |
CA |
78 | 2 |
Contusion, Accidental exposure to product, Exposure via skin contact, Device delivery system issue, Device leakage, |
||||
| 552 | 26409220 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, Device leakage, |
||||
SOMATROPIN, |
||||
| 553 | 26410547 |
US |
19 | 1 |
Injection site urticaria, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 554 | 26410575 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 555 | 26410599 |
US |
83 | 2 |
Injection site pain, Product preparation error, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 556 | 26410620 |
US |
30 | 2 |
Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 557 | 26410640 |
US |
90 | 2 |
Product use in unapproved indication, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 558 | 26410687 |
US |
68 | 1 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 559 | 26410698 |
US |
67 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 560 | 26410729 |
US |
31 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 561 | 26410740 |
US |
1 | |
Injection site pain, Exposure via skin contact, Accidental exposure to product, |
||||
DUPILUMAB, |
||||
| 562 | 26410743 |
US |
73 | 2 |
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 563 | 26410940 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 564 | 26410959 |
US |
68 | 2 |
Productive cough, Nasopharyngitis, Injection site erythema, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 565 | 26410973 |
US |
80 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, INSULIN LISPRO, |
||||
| 566 | 26411009 |
US |
86 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 567 | 26411037 |
US |
72 | 2 |
Dyspnoea, Injection site pain, Accidental exposure to product, Exposure via skin contact, Therapeutic product effect incomplete, |
||||
DUPILUMAB, |
||||
| 568 | 26411125 |
US |
82 | 1 |
Injection site pain, Extra dose administered, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 569 | 26411171 |
US |
77 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE AND LIXISENATIDE, |
||||
| 570 | 26411174 |
US |
68 | 2 |
Product prescribing error, Inappropriate schedule of product administration, Accidental exposure to product, Exposure via skin contact, |
||||
INSULIN GLARGINE, |
||||
| 571 | 26411586 |
US |
72 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, TIRZEPATIDE, |
||||
| 572 | 26412499 |
US |
64 | 2 |
Accidental exposure to product, Exposure via skin contact, Device use error, |
||||
ERENUMAB-AOOE, |
||||
| 573 | 26412705 |
US |
69 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 574 | 26401917 |
US |
60 | 2 |
Instillation site irritation, Pruritus, Rash erythematous, Product quality issue, Wrong technique in product usage process, Exposure via skin contact, Prescribed underdose, Inappropriate schedule of product administration, |
||||
PERFLUOROHEXYLOCTANE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, OXCARBAZEPINE, LISDEXAMFETAMINE DIMESYLATE, LISDEXAMFETAMINE, LISDEXAMFETAMINE DIMESYLATE CAPSULES, FLUOXETINE HYDROCHLORIDE, GABAPENTIN, |
||||
| 575 | 26401998 |
US |
75 | 2 |
Device delivery system issue, Device failure, Accidental exposure to product, Exposure via skin contact, |
||||
ABATACEPT, |
||||
| 576 | 26402077 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
EVOLOCUMAB, |
||||
| 577 | 26402232 |
US |
1 | |
Accidental exposure to product, Device leakage, Drug dose omission by device, Exposure via skin contact, Device delivery system issue, Incorrect dose administered by device, |
||||
SECUKINUMAB, SECUKINUMAB, |
||||
| 578 | 26402715 |
US |
1 | |
Needle track marks, Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, Product complaint, |
||||
MEPOLIZUMAB, ALBUTEROL SULFATE AND BUDESONIDE, SEMAGLUTIDE, ORAL SEMAGLUTIDE, CETIRIZINE, CETIRIZINE HYDROCHLORIDE, CETIIRIZINE, |
||||
| 579 | 26402968 |
US |
63 | 1 |
Intentional product misuse, Accidental exposure to product, Product administration error, Exposure via skin contact, |
||||
EVOLOCUMAB, EVOLOCUMAB, |
||||
| 580 | 26403047 |
US |
25 | 1 |
Device difficult to use, Accidental exposure to product, Exposure via skin contact, Device use error, Drug dose omission by device, |
||||
ERENUMAB-AOOE, |
||||
| 581 | 26403174 |
US |
72 | 2 |
Exposure via skin contact, Wrong technique in device usage process, Accidental exposure to product, Product dose omission issue, |
||||
MEPOLIZUMAB, |
||||
| 582 | 26403695 |
US |
63 | 1 |
Injection site haemorrhage, Accidental exposure to product, Exposure via skin contact, Wrong technique in product usage process, Product knowledge deficit, Device use error, |
||||
EVOLOCUMAB, |
||||
| 583 | 26404368 |
US |
82 | 2 |
Device delivery system issue, Accidental exposure to product, Exposure via skin contact, Product knowledge deficit, Off label use, |
||||
ABATACEPT, ALENDRONATE SODIUM, AMLODIPINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, FUROSEMIDE, LEVOTHYROXINE SODIUM, LEVOTHYROXINE SODIUM ANHYDROUS, MAGNESIUM, METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, METOPROLOL TARTRATE, METOPROLOL, MONTELUKAST SODIUM, MONTELUKAST, PREDNISONE, RABEPRAZOLE, SERTRALINE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ERGOCALCIFEROL, |
||||
| 584 | 26404718 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 585 | 26404723 |
US |
72 | 2 |
Accidental exposure to product, Exposure via skin contact, Injection site pain, |
||||
DUPILUMAB, RISANKIZUMAB-RZAA, ADALIMUMAB, |
||||
| 586 | 26404729 |
US |
64 | 2 |
Rash pruritic, Accidental exposure to product, Exposure via skin contact, Asthma, |
||||
DUPILUMAB, |
||||
| 587 | 26404733 |
US |
1 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 588 | 26404764 |
US |
||
Injection site pain, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 589 | 26404790 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 590 | 26404891 |
US |
78 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 591 | 26404899 |
US |
45 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 592 | 26404971 |
US |
65 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 593 | 26405006 |
US |
72 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 594 | 26405045 |
US |
63 | 2 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 595 | 26405075 |
US |
80 | 2 |
Accidental exposure to product, Exposure via skin contact, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 596 | 26405076 |
US |
17 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 597 | 26405104 |
US |
2 | |
Accidental exposure to product, Exposure via skin contact, |
||||
SARILUMAB, ALENDRONATE SODIUM, AZITHROMYCIN, AZITHROMYCIN MONOHYDRATE, AZITHROMYCIN DIHYDRATE, PREDNISONE, ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, FILM COATED, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 598 | 26405120 |
US |
78 | 1 |
Accidental exposure to product, Exposure via skin contact, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 599 | 26405498 |
US |
81 | 1 |
Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
| 600 | 26406097 |
US |
75 | 2 |
Off label use, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28